Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BioDuro and Sundia Merge to Form China-US CRDMO Backed by Advent

publication date: Sep 25, 2020

BioDuro and Sundia, two pre-clinical China-US CROs, have merged to form one of the largest CRDMOs with operations in China and the US. As part of the deal, Advent, a Boston  private equity investor, will lead a majority investment in Sundia. In early 2019, Advent acquired control of BioDuro, also via a majority investment. The new company, which will operate as BioDuro-Sundia, will offer drug discovery, development and manufacturing for both APIs and drug products. Bridgewest Capital was a co-investor in Sundia. Financial terms were not disclosed. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital